CAICaris Life Sciences, Inc.
Services-Medical Laboratories
- Revenue
- $812M
- 97% YoY
- Operating margin
- 5.6%
- 109% YoY
- EBITDA
- $68M
- 133% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -6.3×
- −$427M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear9% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear2% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|
| Revenue | $306M | $412M | $812M | 97% |
| Operating income | −$320M | −$257M | $45M | 118% |
| Net income | −$341M | −$282M | −$68M | 76% |
| Operating cash flow | −$276M | −$245M | $83M | 134% |
| Capex | $22M | $8M | $16M | 93% |
| Stock-based comp | $15M | $19M | $70M | 276% |
| Buybacks | $0 | $0 | $113K |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $12M · 2
- Net
- −$12M
Pay vs performance
No pay-versus-performance disclosure yet.